Concepedia

Julie Rihani

JR

Statistics

Publications

4

Citations

152

H-Index

4

Active since

2023

Affiliations

National Taiwan University Hospital(Current)

Novartis (Switzerland)

National Cancer Centre Singapore

Acıbadem University

Cairo University

Julie Rihani is an author at National Taiwan University Hospital specializing in medicine, oncology, and breast oncology.

Publications per year

2023–2024

4

Publications

4

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Journal of Clinical Oncology · 2024 · 79 citations · Full text

Medicine, Oncology, Pharmacology +17

Abstract GS1-10: Primary results from the randomized Phase II RIGHT Choice trial of premenopausal patients with aggressive HR+/HER2− advanced breast cancer treated with ribociclib + endocrine therapy vs physician’s choice combination chemotherapy

Yen‐Shen Lu, Eznal Izwadi Bin Mohd Mahidin, Hamdy A. Azim et al. · Cancer Research · 2023 · 41 citations

Medicine, Oncology, Pharmacology +16

Quality of Life and Treatment-Related Side Effects in Patients With HR+/HER2− Advanced Breast Cancer: Findings From a Multicountry Survey

Fátima Cardoso, Julie Rihani, Victoria Harmer et al. · The Oncologist · 2023 · 22 citations · Full text

Medicine, Oncology, Breast Oncology +7

Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial.

Nagi S. El Saghir, Yoon Sim Yap, Yeşim Eralp et al. · Journal of Clinical Oncology · 2023 · 10 citations

Medicine, Oncology, Pharmacology +12

1–4 of 4